Whereas, if significant portions of circulating sclerostin are of vascular origin in CKD, inhibition of sclerostin function by a monoclonal antibody would worsen vascular calcification while improving bone remodeling/formation (Figure 7). The gene discussed is SOST; the disease is chronic kidney disease.